Piramal Pharma gets ESG Rating of 65 for FY26, up from 64
Piramal Pharma Limited received an ESG Rating of 65 for FY25-26 from NSE Sustainability Ratings and Analytics Limited, an improvement from its previous score of 64. The rating was voluntarily assigned by NSE Sustainability based on publicly available data.
An ESG rating improvement is generally positive but typically does not have an immediate, significant impact on stock price or business operations unless it's a major shift or linked to specific investment criteria.
The company's ESG rating has improved, indicating positive progress in its sustainability and responsible operations.
Piramal Pharma Limited (PPL) has received an improved Environment, Social, and Governance (ESG) Rating of 65 for the Financial Year 2025-26. This rating was assigned by NSE Sustainability Ratings and Analytics Limited, marking an increase from the previous score of 64.
The rating is based on data made available by the Company in the public domain for FY25-26. PPL has stated that it did not engage NSE Sustainability for this ESG rating; the report was prepared voluntarily by NSE Sustainability considering the ESG factors reported by the Company.
The Company Secretary & Compliance Officer, Maneesh Sharma, informed that this intimation is for information and record and is also being uploaded on Piramal Pharma Limited's website.
A plain-language summary of a public exchange filing by Piramal Pharma Limited. Read the original for the full detail.